Amedisys, Inc. (NASDAQ: AMED), one of America’s leading home health and
hospice care companies, today announced the appointment of Nathaniel M.
Zilkha to the Company’s Board of Directors. Mr. Zilkha is a Member of
the general partner of KKR & Co. L.P. (together with its affiliates,
“KKR”) and serves as Head of KKR’s credit platform and as its Global
Co-Head of Special Situations. With this addition, the Company’s Board
now comprises seven directors.
“We are pleased to welcome Nat Zilkha to our Board of Directors and look
forward to his contributions,” said Donald A. Washburn, Co-Chairman of
the Board. “The Amedisys Board and leadership team continues to be
focused on building value for our stockholders through improving the
Company’s financial performance, maintaining the highest quality,
patient-centered services for our patients across the country, and
upholding our firm commitment to compliance.”
“Creating stockholder value is a top priority for the Amedisys Board
during this period of transition for Amedisys as we align our business
to the sweeping change taking place across the health care industry,”
said David R. Pitts, Co-Chairman of the Board. “To that end, we welcome
the expertise and energy that Nat Zilkha will bring as the newest
addition to our Board, and we appreciate the vote of confidence that KKR
has shown in our Company by virtue of the investment that it has made.”
“I am delighted to join the Board of Amedisys,” said Mr. Zilkha. “We see
great potential in the home health and hospice space, and we believe
Amedisys is well positioned to capitalize on this opportunity. I look
forward to working with my fellow Board members and Amedisys’ senior
management to position the Company for strong future performance.”
About Amedisys:
Amedisys, Inc. (NASDAQ: AMED) is a “health care at home” company
delivering personalized home health and hospice care to more than
360,000 patients each year. Amedisys is focused on delivering the care
that is best for our patients, whether that is home-based recovery and
rehabilitation after an operation or injury, care focused on empowering
them to manage a chronic disease, palliative care for those with a
terminal illness, or hospice care at the end of life. For more
information about Amedisys, please visit: http://www.amedisys.com.
We use our company website as a channel of distribution for important
company information. Important information, including press releases,
analyst presentations and financial information regarding the Company is
routinely posted on and accessible on the “Investor Relations” subpage
of our website, which is accessible by clicking on the tab labeled
“Investors” on our website home page. We will also use our website to
expedite public access to time-critical information regarding the
Company in advance of or in lieu of distributing a press release or a
filing with the Securities and Exchange Commission (“SEC”) disclosing
the same information. In addition, we make available on the Investor
Relations subpage of our website (under the link “SEC filings”) free of
charge our annual reports on Form 10-K, quarterly reports on Form 10-Q,
current reports on Form 8-K, ownership reports on Forms 3, 4 and 5 and
any amendments to those reports as soon as practicable after we
electronically file such reports with the SEC. Further, copies of our
Certificate of Incorporation and Bylaws, our Code of Ethical Business
Conduct and the charters for the Audit, Compensation, Nominating and
Corporate Governance, Quality of Care and Compliance and Ethics
Committees of our Board are also available on the Investor Relations
subpage of our website (under the link “Corporate Governance”).
Bio Attached
NATHANIEL M. ZILKHA
Member – Board of Directors
Mr. Zilkha joined KKR in 2007 and serves as Head of KKR’s credit
platform and as its Global Co-Head of Special Situations. As Head of
Credit, he works closely with the credit portfolio teams to help drive
investment performance, strategy, business development and coordination
across the platform. He is a member of the Leveraged Credit, Private
Credit and Special Situations Investment Committees as well as the KKR
Asset Management Portfolio Management Committee. He also spent time as a
member of the Healthcare Private Equity Team in KKR’s Menlo Park office.
Prior to joining KKR, Mr. Zilkha was a member of the Principal
Investment Area of Goldman, Sachs & Co., where he invested in private
equity and principal debt transactions. He is currently on the Boards of
Directors of Amedisys, Inc., the Winoa Group and QMH Limited. He was
formerly on the Boards of Directors of Harden Healthcare, Oriental
Brewery and Jazz Pharmaceuticals. Mr. Zilkha graduated cum laude from
Princeton University.
Copyright Business Wire 2014